Vericel Corporation reported significant financial performance improvements in its latest quarterly filing, with total revenue reaching $77.5 million for the three months ended June 30, 2026, a 22.5% increase from $63.2 million in the same period last year. For the first half of 2026, revenue totaled $145.9 million, up 25.9% from $115.8 million in the first half of 2025. The company achieved a net income of $2.2 million for the second quarter, a substantial turnaround from a net loss of $553,000 in the prior year. This marks a notable improvement in profitability, with the net loss for the first half of 2026 narrowing to $4.1 million from $11.8 million in the same period of 2025.
The growth in revenue was primarily driven by increased sales of the company's flagship products, MACI and Epicel. MACI product sales alone accounted for $65.5 million in the second quarter, reflecting a 22.5% increase year-over-year. Epicel also saw a 20.8% increase in sales, contributing $10.4 million in the same quarter. The company’s gross profit for the second quarter was $56.4 million, representing a 21% increase compared to the previous year, attributed to higher sales volumes and a fixed manufacturing cost structure.
In terms of operational developments, Vericel has made strategic advancements, including the FDA approval for MACI's arthroscopic delivery method, which is expected to enhance the product's adoption among orthopedic surgeons. The company is also expanding its manufacturing capabilities at its new facility in Burlington, Massachusetts, which received FDA approval for MACI production in March 2026. This facility is anticipated to become the primary manufacturing site for both MACI and Epicel, further supporting the company's growth strategy.
As of June 30, 2026, Vericel reported total assets of $502.9 million, with cash and cash equivalents amounting to $125.4 million. The company has also entered into a ten-year agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $196.9 million, aimed at procuring NexoBrid and developing a U.S.-based manufacturing facility. This agreement is expected to bolster Vericel's market position in the burn care sector.
Looking ahead, Vericel anticipates continued growth driven by its expanding product portfolio and market penetration strategies. The company plans to leverage its recent FDA approvals and the BARDA agreement to enhance its operational capabilities and product offerings. With a strong cash position and ongoing investments in research and development, Vericel is well-positioned to navigate the competitive landscape of biopharmaceuticals and medical technologies.
About Vericel Corp
Vericel Corporation is a biopharmaceutical company specializing in advanced cell therapies for sports medicine and severe burn care. Its core products include FDA-approved autologous cell therapies MACI and Epicel, and the biologic NexoBrid licensed from MediWound. The company develops innovative biologic and tissue engineering solutions, serving orthopedic and burn treatment markets in the U.S., with a focus on improving patient outcomes and expanding minimally invasive procedures.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov